STERIS is expected to report consensus revenue of $1.56 billion and adjusted EPS of $2.67, with its current stock price of $232.15 trading approximately 14% below the average analyst target of $271.33. Investors are primarily focused on the performance of the Healthcare segment, specifically the sustainability of surgical procedural volumes and the strategic integration of the recently announced $2.1 billion acquisition of Xodus Medical.
Recent results demonstrated resilient 7.3% top-line growth driven by healthcare consumables and services, though margins remain a point of concern due to ongoing tariff headwinds and elevated capital spending. Management's ability to reaffirm its full-year fiscal 2027 EPS guidance of $11.00-$11.30 will be critical for sentiment as the company scales its manufacturing capacity in North Carolina.